|
Re: IR
|
2
|
Resverlogix Corp.
|
Jan 18, 2023 02:56PM
|
|
Re: Some history
|
1
|
Resverlogix Corp.
|
Jan 25, 2023 12:19PM
|
|
Re: Some history
|
2
|
Resverlogix Corp.
|
Jan 25, 2023 01:21PM
|
|
Re: Some history
|
1
|
Resverlogix Corp.
|
Jan 25, 2023 01:33PM
|
|
Re: Some history
|
2
|
Resverlogix Corp.
|
Jan 25, 2023 02:10PM
|
|
Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
|
1
|
Zenith Epigenetics
|
Jan 26, 2023 01:08PM
|
|
Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
|
|
Zenith Epigenetics
|
Jan 27, 2023 09:43AM
|
|
Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
|
|
Zenith Epigenetics
|
Jan 27, 2023 10:20AM
|
|
Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
|
|
Zenith Epigenetics
|
Jan 27, 2023 11:18AM
|
|
Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
|
3
|
Zenith Epigenetics
|
Jan 27, 2023 02:47PM
|
|
Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
|
1
|
Zenith Epigenetics
|
Jan 29, 2023 09:27AM
|
|
Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
|
2
|
Zenith Epigenetics
|
Jan 29, 2023 11:16AM
|
|
Re: Zenith trial partners
|
3
|
Zenith Epigenetics
|
Jan 30, 2023 06:05PM
|
|
Re: Zenith trial partners
|
2
|
Zenith Epigenetics
|
Jan 31, 2023 10:27AM
|
|
Re: Zenith trial partners
|
2
|
Zenith Epigenetics
|
Feb 01, 2023 08:07PM
|
|
Re: Zenith trial partners
|
2
|
Zenith Epigenetics
|
Feb 01, 2023 11:14PM
|
|
A Leak
|
|
Resverlogix Corp.
|
Feb 02, 2023 10:30AM
|
|
Re: Zenith trial partners
|
2
|
Zenith Epigenetics
|
Feb 02, 2023 12:31PM
|
|
Re: Zenith trial partners
|
2
|
Zenith Epigenetics
|
Feb 02, 2023 03:59PM
|
|
Re: Zenith trial partners
|
1
|
Zenith Epigenetics
|
Feb 02, 2023 06:54PM
|
